complement pathways


Also found in: Wikipedia.

complement pathways

1. the classical complement pathway (initiated usually by binding of C1 to IgG or IgM antibody to C1) is a complex of three subunits: C1q, C1r, and C1s. After C1q is bound, C1r (an overbar indicates enzymatic activity) cleaves C1s to C1s. C1s cleaves both C4 into C4a and C4b as well as C2 into C2a and C2b. C2b combines with C4b to form C4b2b, which is a C3 convertase. C3 convertase cleaves C3 into C3a and C3b. C3b joins C4bC2b to form a C5 convertase (also known as C4b2b3b), which cleaves C5 into C5a and C5b. After C5b has been bound to the cell surface, the remainder of the complement components (C6-C9) as well as C5b form the membrane attack complex (MAC). MAC causes a hole in the cell membrane.
2. in the alternative complement pathway, surface-bound C3b binds factor B, which is cleaved by factor D into Ba and Bb. C3bBb is an unstable C3 convertase unless properdin (P) binds to it to form C3bBbP. The stable C3 convertase generates more C3b. When a complex of C3bBbC3b is formed, this is the alternative pathway C5 convertase. From C5b through C9, the classical and alternative pathways are the same.
3. In the lectin-binding pathway, mannose-binding protein initiates the pathway, which then uses components of the classical complement pathway. Some of the "a" components of both pathways have various biologic activities, that is, C3a is an anaphylatoxin.

com·ple·ment path·ways

(kom'plĕ-mĕnt path'wāz)
1. The classical complement pathway (initiated usually by binding of C1 to IgG or IgM antibody to C1) is a complex of three subunits: C1q, C1r, and C1s. After C1q is bound, C1r (an overbar indicates enzymatic activity) cleaves C1s to C1s. C1s cleaves both C4 into C4a and C4b as well as C2 into C2a and C2b. C2b combines with C4b to form C4b2b, which is a C3 convertase. C3 convertase cleaves C3 into C3a and C3b. C3b joins C4bC2b to form a C5 convertase (also known as C4b2b3b), which cleaves C5 into C5a and C5b. After C5b is bound to the cell surface the remainder of the complement components (C6-C9) as well as C5b form the membrane attack complex (MAC). MAC causes a hole in the cell membrane.
2. In the alternative complement pathway, surface-bound C3b binds Factor B, which is cleaved by Factor D into Ba and Bb. C3bBb is an unstable C3 convertase unless properdin (P) binds to it to form C3bBbP. The stable C3 convertase generates more C3b. When a complex of C3bBbC3b is formed, this is the alternative pathway C5 convertase. From C5b through C9, the classical and alternative pathways are the same.
3. In the lectin-binding pathway, mannose-binding protein (MBP) initiates the pathway, which then uses components of the classical complement pathway. Some of the "a" components of both pathways have various biologic activities, i.e., C3a is an anaphylatoxin.
References in periodicals archive ?
1994), Epstein-Barr-Viruses activating both complement pathways (Mayes et al.
For testing alternative complement pathway activity rabbit erythrocytes (RRBC) were used as foreign surfaces.
Apellis is a clinical stage immunotherapy company and targets the complement pathways to correct auto-immune conditions.
While these two pathways differ from the classical pathway in their initial activation, all three complement pathways converge to similar outcomes.
Six impaired both complement pathways (classical and alternative): stem bark from Astronium urundeuvea (Anacardiaceae).
Senescence of the immune system function could interfere with transmissible spongiform encephalopathy pathogenesis in other ways as well, such as impairing migrating intestinal dendritic cells or complement pathways involved in complexing Pr[P.
Boswellia extracts also have been shown to decrease polymorphonuclear leukocyte infiltration to areas of inflammation and trauma and to inhibit both the classical and alternative complement pathways (Phytomedicine 3:77-81, 1996).
Celldex's previous clinical experience with CDX-1135 in over 500 patients in other indications has shown a good safety profile and potent inhibition of complement pathways.
Modulation of cell growth was evaluated by tritiated thymidine incorporation while inhibition of complement activity was measured on both classical and alternative complement pathways (CP and AP respectively).
About Apellis Apellis is a clinical stage immunotherapy company and targets the complement pathways to correct auto-immune conditions.
CR2-Crry is an inhibitor of the alternative, classical and lectin complement pathways whereas TT30 inhibits only the alternative pathway.
Complement activation in these clinical indications may involve both the classical and alternative complement pathways.

Full browser ?